| Bioactivity | HCV-IN-39 (Compound 18a) is a potent hepatitis C virus (HCV) nucleoside inhibitor with EC50 values of 0.644, 0.952 and 0.154 μM against GT1a, GT1b and GT1b CES1 replicons[1]. |
| Target | EC50: 0.644 μM (GT1a), 0.952 μM (GT1b), 0.154 μM (GT1b CES1) |
| Name | HCV-IN-39 |
| CAS | 2087916-31-0 |
| Formula | C21H26BrClN3O9P |
| Molar Mass | 610.78 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Chris Krueger A, et al. Synthesis and evaluation of 2'-dihalo ribonucleotide prodrugs with activity against hepatitis C virus. Bioorg Med Chem. 2020 Jan 1;28(1):115208. |
HCV-IN-39
CAS: 2087916-31-0 F: C21H26BrClN3O9P W: 610.78
HCV-IN-39 (Compound 18a) is a potent hepatitis C virus (HCV) nucleoside inhibitor with EC50 values of 0.644, 0.952 and 0
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.